BioLife Solutions (BLFS) Set to Announce Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect BioLife Solutions to announce earnings of $0.05 per share and revenue of $29.13 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.88. The company had revenue of $28.47 million during the quarter, compared to analysts’ expectations of $27.80 million. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%. On average, analysts expect BioLife Solutions to post $0.03 EPS for the current fiscal year and $0.16 EPS for the next fiscal year.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $38.61 on Thursday. The company has a market cap of $1.89 billion, a P/E ratio of 33.28 and a beta of 1.82. The business has a 50-day simple moving average of $37.46 and a two-hundred day simple moving average of $27.81. BioLife Solutions has a 52-week low of $17.86 and a 52-week high of $39.76.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on BLFS shares. TD Cowen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and cut their price objective for the company from $33.00 to $31.00 in a research report on Wednesday, July 22nd. Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 21st. HC Wainwright downgraded shares of BioLife Solutions from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $32.00 to $31.00 in a report on Thursday, July 23rd. Lake Street Capital lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and cut their target price for the company from $33.00 to $31.00 in a report on Wednesday, July 22nd. Finally, William Blair set a $31.00 price target on BioLife Solutions in a research report on Thursday, July 23rd. One analyst has rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, BioLife Solutions has an average rating of “Hold” and an average target price of $31.38.

About BioLife Solutions

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.